Department of Oncology, The First Affiliated Hospital of the Henan University of Science and Technology, Jinghua Road No. 24, Jianxi District, Luoyang City, 471003, Henan, People's Republic of China,
Breast Cancer. 2014 Jan;21(1):1-9. doi: 10.1007/s12282-013-0497-8. Epub 2013 Oct 8.
Due to the heterogeneity of lymph node examination and the conflicting results existing for the same classification of lymph node ratio (LNR), it is necessary to conduct a meta-analysis to evaluate the prognostic effects of different LNRs on breast cancer. PubMed, EMBASE, and ISI Web of Knowledge were searched to find all published cohort studies that evaluated the prognostic value of different LNRs on breast cancer. The outcomes were overall survival (OS), disease-free survival (DFS), breast cause-special survival (BCCS), mortality, locoregional recurrence (LRR), and distant metastasis. Data was analyzed using comprehensive meta-analysis software version 2.0, and 23 studies were included. The available evidence showed that LNR was a prognostic predictor for breast cancer, especially for clinically node-positive breast cancer, but the available evidence could not judge which cutoff point is the most reliable. Meanwhile, the cutoff values 0.2 and 0.65 could be suitable to predict breast cancer OS, DFS, BCCS, and mortality.
由于淋巴结检查的异质性以及相同淋巴结比率 (LNR) 分类存在冲突的结果,有必要进行荟萃分析来评估不同 LNR 对乳腺癌的预后影响。检索了 PubMed、EMBASE 和 ISI Web of Knowledge,以查找所有评估不同 LNR 对乳腺癌预后价值的已发表队列研究。结果是总生存 (OS)、无病生存 (DFS)、乳腺癌特异性生存 (BCCS)、死亡率、局部区域复发 (LRR) 和远处转移。使用综合荟萃分析软件版本 2.0 分析数据,并纳入了 23 项研究。现有证据表明,LNR 是乳腺癌的预后预测因子,尤其是对临床淋巴结阳性的乳腺癌,但现有证据尚无法判断哪个截断值最可靠。同时,截断值 0.2 和 0.65 可能适合预测乳腺癌 OS、DFS、BCCS 和死亡率。